Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Richard Muwonge is active.

Publication


Featured researches published by Richard Muwonge.


The New England Journal of Medicine | 2009

HPV Screening for Cervical Cancer in Rural India

Rengaswamy Sankaranarayanan; Bhagwan M. Nene; Surendra Shastri; Kasturi Jayant; Richard Muwonge; Atul M. Budukh; Sanjay Hingmire; Sylla G. Malvi; Ranjit Thorat; Ashok Kothari; Roshan F. Chinoy; Rohini Kelkar; Shubhada Kane; Sangeetha Desai; Vijay R. Keskar; Raghevendra Rajeshwarkar; Nandkumar S Panse; Ketayun A. Dinshaw

BACKGROUND In October 1999, we began to measure the effect of a single round of screening by testing for human papillomavirus (HPV), cytologic testing, or visual inspection of the cervix with acetic acid (VIA) on the incidence of cervical cancer and the associated rates of death in the Osmanabad district in India. METHODS In this cluster-randomized trial, 52 clusters of villages, with a total of 131,746 healthy women between the ages of 30 and 59 years, were randomly assigned to four groups of 13 clusters each. The groups were randomly assigned to undergo screening by HPV testing (34,126 women), cytologic testing (32,058), or VIA (34,074) or to receive standard care (31,488, control group). Women who had positive results on screening underwent colposcopy and directed biopsies, and those with cervical precancerous lesions or cancer received appropriate treatment. RESULTS In the HPV-testing group, cervical cancer was diagnosed in 127 subjects (of whom 39 had stage II or higher), as compared with 118 subjects (of whom 82 had advanced disease) in the control group (hazard ratio for the detection of advanced cancer in the HPV-testing group, 0.47; 95% confidence interval [CI], 0.32 to 0.69). There were 34 deaths from cancer in the HPV-testing group, as compared with 64 in the control group (hazard ratio, 0.52; 95% CI, 0.33 to 0.83). No significant reductions in the numbers of advanced cancers or deaths were observed in the cytologic-testing group or in the VIA group, as compared with the control group. Mild adverse events were reported in 0.1% of screened women. CONCLUSIONS In a low-resource setting, a single round of HPV testing was associated with a significant reduction in the numbers of advanced cervical cancers and deaths from cervical cancer.


The Lancet | 2007

Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial

Rengaswamy Sankaranarayanan; Pulikkottil Okkuru Esmy; Rajamanickam Rajkumar; Richard Muwonge; Rajaraman Swaminathan; Sivanandam Shanthakumari; Jean-Marie Fayette; Jacob Cherian

BACKGROUND Cervical cancer is the most common cancer among women in developing countries. We assessed the effect of screening using visual inspection with 4% acetic acid (VIA) on cervical cancer incidence and mortality in a cluster randomised controlled trial in India. METHODS Of the 114 study clusters in Dindigul district, India, 57 were randomised to one round of VIA by trained nurses, and 57 to a control group. Healthy women aged 30 to 59 years were eligible for the study. Screen-positive women had colposcopy, directed biopsies, and, where appropriate, cryotherapy by nurses during the screening visit. Those with larger precancerous lesions or invasive cancers were referred for appropriate investigations and treatment. Cervical cancer incidence and mortality in the study groups were analysed and compared using Cox regression taking the cluster design into account, and analysis was by intention to treat. The primary outcome measures were cervical cancer incidence and mortality. RESULTS Of the 49,311 eligible women in the intervention group, 31,343 (63.6%) were screened during 2000-03; 30,958 control women received the standard care. Of the 3088 (9.9%) screened positive, 3052 had colposcopy, and 2539 directed biopsy. Of the 1874 women with precancerous lesions in the intervention group, 72% received treatment. In the intervention group, 274,430 person years, 167 cervical cancer cases, and 83 cervical cancer deaths were accrued compared with 178,781 person-years, 158 cases, and 92 deaths and in the control group during 2000-06 (incidence hazard ratio 0.75 [95% CI 0.55-0.95] and mortality hazard ratio 0.65 [0.47-0.89]). INTERPRETATION VIA screening, in the presence of good training and sustained quality assurance, is an effective method to prevent cervical cancer in developing countries.


The Lancet | 2005

Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial

Rengaswamy Sankaranarayanan; Kunnambath Ramadas; Gigi Thomas; Richard Muwonge; Somanathan Thara; Babu Mathew; Balakrishnan Rajan

BACKGROUND Oral cancer is common in men from developing countries, and is increased by tobacco and alcohol use. We aimed to assess the effect of visual screening on oral cancer mortality in a cluster-randomised controlled trial in India. METHODS Of the 13 clusters chosen for the study, seven were randomised to three rounds of oral visual inspection by trained health workers at 3-year intervals and six to a control group during 1996-2004, in Trivandrum district, Kerala, India. Healthy participants aged 35 years and older were eligible for the study. Screen-positive people were referred for clinical examination by doctors, biopsy, and treatment. Outcome measures were survival, case fatality, and oral cancer mortality. Oral cancer mortality in the study groups was analysed and compared by use of cluster analysis. Analysis was by intention to treat. FINDINGS Of the 96,517 eligible participants in the intervention group, 87,655 (91%) were screened at least once, 53,312 (55%) twice, and 29,102 (30%) three times. Of the 5145 individuals who screened positive, 3218 (63%) complied with referral. 95,356 eligible participants in the control group received standard care. 205 oral cancer cases and 77 oral cancer deaths were recorded in the intervention group compared with 158 cases and 87 deaths in the control group (mortality rate ratio 0.79 [95% CI 0.51-1.22]). 70 oral cancer deaths took place in users of tobacco or alcohol, or both, in the intervention group, compared with 85 in controls (0.66 [0.45-0.95]). The mortality rate ratio was 0.57 (0.35-0.93) in male tobacco or alcohol users and 0.78 (0.43-1.42) in female users. INTERPRETATION : Oral visual screening can reduce mortality in high-risk individuals and has the potential of preventing at least 37,000 oral cancer deaths worldwide.


International Journal of Cancer | 2004

ACCURACY OF VISUAL SCREENING FOR CERVICAL NEOPLASIA: RESULTS FROM AN IARC MULTICENTRE STUDY IN INDIA AND AFRICA

Rengaswamy Sankaranarayanan; Parthasarathy Basu; Ramani Wesley; Cédric Mahé; Namory Keita; Charles Gombe Mbalawa; Rameshwar Sharma; Amadou Dolo; Surendra Shastri; Marius Nacoulma; Madi Nayama; Thara Somanathan; Eric Lucas; Richard Muwonge; Lucien Frappart; D. Maxwell Parkin

Visual inspection‐based screening tests, such as visual inspection with 4% acetic acid (VIA) and with Lugols iodine (VILI), have been proposed as alternatives to cytology in mass screening programs. To date, there is only limited information on the accuracy of these tests in detecting High‐grade Squamous Intraepithelial Lesions (HSIL). Eleven cross‐sectional studies involving 56,939 women aged 25–65 years were conducted in Burkina Faso, Congo, Guinea, India, Mali and Niger to evaluate the accuracy of VIA and VILI performed by health workers. A common protocol and questionnaire was used. For final diagnosis, all women were investigated with colposcopy and biopsies were taken when necessary. Data from the studies were pooled to calculate sensitivity, specificity and predictive values of the tests for the detection of HSIL. Of the screened women, 16.1% and 16.4% were positive on examination using, respectively, VIA and VILI; 1,063 were diagnosed with HSIL. The pooled sensitivity, specificity, positive and negative predictive values for VIA were 76.8% (95% CI: 74.2–79.4%), 85.5% (95% CI: 85.2–85.8%), 9.4% (95% CI:8.8–10.8%) and 99.5% (95% CI:99.4–99.6%), respectively. The values were 91.7% (95% CI: 89.7–93.4%), 85.4% (95% CI: 85.1–85.7%), 10.9% (95% CI: 10.2–11.6%) and 99.8% (95% CI:99.7–99.9%), respectively for VILI. The range of sensitivity and specificity for VIA was 56.1–93.9% and 74.2–93.8%, respectively, between studies and were 76.0–97.0 % and 73.0–91.3% for VILI. VILI had a significantly higher sensitivity than VIA in detecting HSIL, but specificity was similar. VILI appears to be a more accurate visual test for use in screening and treatment programs in low‐resource settings.


International Journal of Cancer | 2008

Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India.

Marc Arbyn; Rengaswamy Sankaranarayanan; Richard Muwonge; Namory Keita; Amadou Dolo; Charles Gombe Mbalawa; Hassan Nouhou; Boblewende Sakande; Ramani Wesley; Thara Somanathan; Anjali Sharma; Surendra Shastri; Parthasarathy Basu

Cervical cancer is the main cancer among women in sub‐Saharan Africa, India and other parts of the developing world. Evaluation of screening performance of effective, feasible and affordable early detection and management methods is a public health priority. Five screening methods, naked eye visual inspection of the cervix uteri after application of diluted acetic acid (VIA), or Lugols iodine (VILI) or with a magnifying device (VIAM), the Pap smear and human papillomavirus testing with the high‐risk probe of the Hybrid Capture‐2 assay (HC2), were evaluated in 11 studies in India and Africa. More than 58,000 women, aged 25–64 years, were tested with 2–5 screening tests and outcome verification was done on all women independent of the screen test results. The outcome was presence or absence of cervical intraepithelial neoplasia (CIN) of different degrees or invasive cervical cancer. Verification was based on colposcopy and histological interpretation of colposcopy‐directed biopsies. Negative colposcopy was accepted as a truly negative outcome. VIA showed a sensitivity of 79% (95% CI 73–85%) and 83% (95% CI 77–89%), and a specificity of 85% (95% CI 81–89%) and 84% (95% CI 80–88%) for the outcomes CIN2+ or CIN3+, respectively. VILI was on average 10% more sensitive and equally specific. VIAM showed similar results as VIA. The Pap smear showed lowest sensitivity, even at the lowest cutoff of atypical squamous cells of undetermined significance (57%; 95% CI 38–76%) for CIN2+ but the specificity was rather high (93%; 95% CI 89–97%). The HC2‐assay showed a sensitivity for CIN2+ of 62% (95% CI 56–68%) and a specificity of 94% (95% CI 92–95%). Substantial interstudy variation was observed in the accuracy of the visual screening methods. Accuracy of visual methods and cytology increased over time, whereas performance of HC2 was constant. Results of visual tests and colposcopy were highly correlated. This study was the largest ever done that evaluates the cross‐sectional accuracy of screening tests for cervical cancer precursors in developing countries. The merit of the study was that all screened subjects were submitted to confirmatory investigations avoiding to verification bias. A major finding was the consistently higher sensitivity but equal specificity of VILI compared with VIA. Nevertheless, some caution is warranted in the interpretation of observed accuracy measures, since a certain degree of gold standard misclassification cannot be excluded. Because of the correlation between visual screening tests and colposcopy and a certain degree of over‐diagnosis of apparent CIN2+ by study pathologists, it is possible that both sensitivity and specificity of VIA and VILI were overestimated. Gold standard verification error could also explain the surprisingly low sensitivity of HC2, which contrasts with findings from other studies.


International Journal of Cancer | 2005

A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India†

Rengaswamy Sankaranarayanan; Bhagwan M. Nene; Ketayun A. Dinshaw; Cédric Mahé; Kasturi Jayant; Surendra Shastri; Sylla G. Malvi; Roshini Chinoy; Rohini Kelkar; Atul M. Budukh; Vijay R. Keskar; Raghevendra Rajeshwarker; Richard Muwonge; Shubhada Kane; Donald Maxwell Parkin

The impact of screening by visual inspection with acetic acid (VIA), cytology or HPV testing on cervical cancer incidence and mortality is investigated in a cluster randomized controlled trial in India. We report findings after the screening phase, when 52 clusters, with a total of 142,701 women aged 30–59 years in Osmanabad District, India, were randomized into 4 arms for a single round of screening by trained midwives with either VIA, cytology or HPV testing as well as a control group. All laboratory tests were done locally. Test‐positive women underwent investigations (colposcopy/biopsy) and treatment in the base hospital. Data on participation, test positivity, positive predictive value and detection rates of cervical neoplasia were analyzed using cluster design methodology. Of the eligible women, 72–74% were screened. Test positivity rates were 14.0% for VIA, 7.0% for cytology and 10.3% for HPV. The detection rate of high‐grade lesions was similar in all intervention arms (0.7% for VIA, 1.0% for cytology and 0.9% for HPV testing) (p = 0.06, Mann‐Whitney test). While the detection rate for VIA dropped to 0.5% with declining test positivity during the course of the study, it remained constant for cytology and HPV testing. Over 85% of women with high‐grade lesions received treatment. Our results show that a high level of participation and good‐quality cytology can be achieved in low‐resource settings. VIA is a useful alternative but requires careful monitoring. Detection rates obtained by HPV testing were similar to cytology, despite higher investments.


International Journal of Gynecology & Obstetrics | 2011

Accuracy of visual inspection with acetic acid for cervical cancer screening

Catherine Sauvaget; Jean-Marie Fayette; Richard Muwonge; Ramani Wesley; Rengaswamy Sankaranarayanan

To provide an updated estimation of the accuracy of visual inspection with acetic acid (VIA) in detecting true disease.


Journal of the National Cancer Institute | 2011

Clinical Breast Examination: Preliminary Results from a Cluster Randomized Controlled Trial in India

Rengaswamy Sankaranarayanan; Kunnambath Ramadas; Somanathan Thara; Richard Muwonge; Jem Prabhakar; Paul Augustine; Muraleedharan Venugopal; Gopan Anju; Beela Sara Mathew

A cluster randomized controlled trial was initiated in the Trivandrum district (Kerala, India) on January 1, 2006, to evaluate whether three rounds of triennial clinical breast examination (CBE) can reduce the incidence rate of advanced disease incidence and breast cancer mortality. A total of 275 clusters that included 115,652 healthy women, aged 30-69 years, were randomly allocated to intervention (CBE; 133 clusters; 55,844 women) or control (no screening; 142 clusters; 59,808 women) groups. Performance characteristics (sensitivity, specificity, false-positive rate, and positive predictive value) of CBE were evaluated. An intention-to-treat analysis was performed for comparison of incidence rates between the intervention and control groups. Preliminary results for incidence are based on follow-up until May 31, 2009, when the first round of screening was completed. Of the 50,366 women who underwent CBE, 30 breast cancers were detected among 2880 women with suspicious findings in CBE screening that warranted further investigations. Sensitivity, specificity, false-positive rate, and positive predictive value of CBE were 51.7% (95% confidence interval [CI] = 38.2% to 65.0%), 94.3% (95% CI = 94.1% to 94.5%), 5.7% (95% CI = 5.5% to 5.9%), and 1.0% (95% CI = 0.7% to 1.5%), respectively. The age-standardized incidence rates for early-stage (stage IIA or lower) breast cancer were 18.8 and 8.1 per 100,000 women and for advanced-stage (stage IIB or higher) breast cancer were 19.6 and 21.7 per 100,000 women, in the intervention and control groups, respectively.


International Journal of Cancer | 2004

Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: Results from a multicenter study in India

Rengaswamy Sankaranarayanan; Ramdas Chatterji; Surendra Shastri; Ramani Wesley; Partha Basu; Cédric Mahé; Richard Muwonge; Daniel Seigneurin; Thara Somanathan; Chinmoy Roy; Rohini Kelkar; Roshini Chinoy; Ketayun A. Dinshaw; Ranajit Mandal; Geethanjali Amin; Smriti Goswami; Smarajit Pal; Sharmila Patil; Namrata Dhakad; Lucien Frappart; Bernard Fontanière

The knowledge that cervical neoplasia are caused by human papillomavirus (HPV) infection has led to the evaluation of its role in screening. We evaluated the accuracy of HPV testing by Hybrid capture II (HC II) method in detecting cervical intraepithelial neoplasia grade 2 and 3 (CIN 2 and 3) lesions in 4 cross‐sectional studies with common protocol and questionnaire in 3 different locations (Kolkata, Mumbai and Trivandrum) in India. These studies involved 18,085 women aged 25–65 years. The reference standard for final diagnosis was a combination of colposcopy/biopsy. All women were investigated with colposcopy and 3,116 received directed biopsy. The sensitivity of HPV testing for detecting CIN 2–3 lesions varied from 45.7% to 80.9% across the study sites; the specificity varied from 91.7% to 94.6% and the positive predictive value from 6.7% to 13.7%. Retesting of 298 randomly chosen denatured samples in France revealed an agreement rate of 85.9% and a κ‐value of 0.72. Although HPV testing seems to be a promising approach for cervical cancer prevention, a large range in sensitivity was observed in our study, possibly due to variations in the quality of specimen collection and reference standards. A higher sensitivity was associated with the center performing the test well. Further developments in terms of more reproducible, less expensive and less sophisticated testing are essential to make the test feasible and effective in low‐resource settings.


Bulletin of The World Health Organization | 2005

Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India

Surendra Shastri; Ketayun A. Dinshaw; Geetanjali Amin; Smriti Goswami; Sharmila Patil; Roshini Chinoy; S. Kane; Rohini Kelkar; Richard Muwonge; Cédric Mahé; Dulhan Ajit; Rengaswamy Sankaranarayanan

OBJECTIVE Naked eye visual inspection with acetic acid (VIA), magnified VIA (VIAM), visual inspection with Lugols iodine (VILI), cytology and human papillomavirus (HPV) testing were evaluated as screening methods for the detection of high-grade squamous intraepithelial lesions (HSIL) of the uterine cervix in a cross-sectional study in Mumbai, India. METHODS Cytology, HPV testing, VIA, VIAM and VILI were carried out concurrently for 4039 women aged 30-65 years. All women were investigated with colposcopy and biopsies were taken from 939 women who had colposcopic abnormalities. The reference standard for final disease status was histology or negative colposcopy. The presence of HSIL was confirmed in 57 women (1.4%). The test characteristics for each method were calculated using standard formulae. RESULTS The sensitivities of cytology, HPV testing, VIA, VIAM and VILI were 57.4%, 62.0%, 59.7%, 64.9%, and 75.4%, respectively (differences were not statistically significant). The specificities were 98.6%, 93.5%, 88.4%, 86.3%, and 84.3%, respectively. Adding a visual test to cytology or HPV testing in parallel combination resulted in a substantial increase in sensitivity, with a moderate decrease in specificity. The parallel combination of VILI and HPV testing resulted in a sensitivity of 92.0% and a specificity of 79.9%. CONCLUSION As a single test, cytology had the best balance of sensitivity and specificity. Visual tests are promising in low-resource settings, such as India. The use of both VIA and VILI may be considered where good quality cytology or HPV testing are not feasible. The sensitivity of cytology and HPV testing increased significantly when combined with VIA or VILI.

Collaboration


Dive into the Richard Muwonge's collaboration.

Top Co-Authors

Avatar

Rengaswamy Sankaranarayanan

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Catherine Sauvaget

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Somanathan Thara

Chittaranjan National Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Kunnambath Ramadas

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Cédric Mahé

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Partha Basu

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge